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1) Department of Internal Medicine and 2) Department of Hepatology and Liver Intensive Care, Assistance Publique—Hôpitaux de Paris, Clichy, FranceAbstractWe performed a retrospective single-centre 1:3 case–control study to investigate the characteristics of vertebral osteomyelitis (VO)
occurring in orthotopic liver transplant (OLT) recipients between 2000 and 2012. Nine cases were identiﬁed in 752 OLT recipients
(1.2%), with a median time from OLT to VO of 12 weeks. In comparison with 27 VO not occurring in OLT patients (controls), VO
occurring in OLT recipients was characterized by decreased levels of inﬂammation biomarkers (average C-reactive protein 65.1 mg$L−1
vs. 167 mg$L−1, p 0.02; average white blood cell count 4.8 × 109$L−1 vs. 12.9 × 109$L−1, p < 0.001), higher rate of fungal infections (3/9
vs. 0/27, p 0.01), lower rate of bacterial infections (3/9 vs. 25/27, p 0.001) and decreased proportion of positive blood cultures (1/9 vs.
16/27, p 0.02) despite a trend towards higher rate of multifocal infection. Microbiologic outcomes were similar between the two groups.
Overall, VO in OLT patients was more difﬁcult to diagnose as a result of altered inﬂammation response and speciﬁc microbial
epidemiology of causal microorganisms.
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University Hospital Center, Tours, FranceIntroductionVertebral osteomyelitis (VO) is a severe infection, mostly
occurring in patients with comorbidities [1]. VO are most
commonly community acquired and are the result of pyogenic
bacteria (ie; Staphylococcus aureus, streptococci and Enter-
obacteriaceae) according to the source of infection [1,2]. An
immunocompromised status, such as immunosuppressive
therapy after solid organ transplantation, could modify the
epidemiology, clinical presentation and outcome of VO. In
particular, orthotopic liver transplant (OLT) patients are at high
risk of infection, notably bloodstream infections due toClinical Microbiology and Infection © 2015 European Society of CEnterobacteriaceae or fungi [3–5]. However, no speciﬁc data
are available concerning VO in OLT recipients.
The aim of this study was to describe the clinical presenta-
tion, microbiologic epidemiology, therapeutic issues and
outcome of VO in OLT recipients.MethodsWe performed a retrospective single-centre study of patients
hospitalized in BeaujonHospital, Clichy, France, between January
2000 and December 2012. Beaujon is a tertiary-care hospital and
reference centre for liver transplantation and for vertebral sur-
gery. We examined the hospital discharge database to identify all
patients corresponding to VO (M463 1–9, M465, M86). Medical
charts corresponding to these codes were critically reviewed to
determine whether they met the deﬁnition of VO and the study
criteria. A VO was deﬁned by speciﬁc radiologic features (mag-
netic resonance imaging or computed tomographic scan) and
ﬁnal physician diagnosis leading to antimicrobial therapy.Clin Microbiol Infect 2015; 21: 573–577
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
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TABLE 1. Characteristics of vertebral osteomyelitis (VO) in patients with or without orthotopic liver transplant
Characteristic Liver transplant (n [ 9) No liver transplant (n [ 27) p
Patients
Average age (y) 52.7 69.1 0.008
Average weight (kg) 66.5 76 0.25
Diabetes mellitus, n (%) 4 (44) 4 (15) 0.08
Average serum creatinine clearance MDRD (mL/min) 88.3 90.2 1
Charlson’s comorbidity index, median (range) 0 (0–3) 1 (0–6) 0.53
Clinical presentation of VO
Spinal pain, n (%) 8 (89) 18 (67) 0.39
Fever (>38°C), n (%) 4 (44) 20 (74) 0.13
Neurologic complication, n (%) 3 (33) 16 (59) 0.26
Radicular neuropathy (n) 2 9
Spinal chord compression (n) 1 7
Delay from clinical signs to radiologic diagnosis (wk), median (range) 5 (1–9) 3 (0.4–28) 0.58
Biologic ﬁndings at diagnosis of VO
Average C-reactive protein (mg/L) 65.1 167 0.02
Average white blood cell count (109/L) 4.8 12.9 <0.001
Radiologic ﬁndings at diagnosis of VO
Location of infection in spine
Cervical (n) 0 5
Thoracic (n) 3 7
Lumbar (n) 4 8
Multifocal (n) 2 7
Soft tissues abscess, n (%) 6 (67) 15 (56) 0.7
Epidural abscess, n (%) 5 (56) 24 (89) 0.05
Microbiologic ﬁndings
Bacterial infection, n (%) 3 (33) 25 (93) 0.001
Staphylococcus aureus (n) 2 8
Coagulase-negative staphylococci (n) 0 1
Streptococcus spp. (n) 0 7
Escherichia coli (n) 1 7
Plurimicrobial (n) 0 2
Fungal infection, n (%) 3 (33) 0 0.01
Aspergillus fumigatus (n) 2
Candida albicans (n) 1
Mycobacterium tuberculosis, n (%) 1 (11) 2 (7) 1
No microbiologic diagnosis, n (%) 2 (22) 0 0.06
Positive blood culture, n (%) 1 (11) 16 (59) 0.02
Computed tomographic scan–guided percutaneous needle biopsy (n) 6 7
Positive culture, n (%) 4 (66) 6 (85) 0.56
Surgical site biopsy (n) 1 8
Positive culture, n (%) 1 6
Microbiologic diagnosis done on another focus of infection (n) 1 2
Other characteristics of infection
Concomitant focus of infection at other site, n (%) 4 (44) 3 (11) 0.05
Endocarditis, n (%) 0 5 (18) 0.3
Antimicrobial therapy
Total duration (wk), median (range) 12 (6–88) 12 (6–52) 0.16
Time from clinical signs to antimicrobial therapy (wk), median (range) 6 (3–10) 2 (0–30) 0.07
Time from radiologic diagnosis to antimicrobial therapy (wk), median (range) 9.5 (0–14) 2.5 (0–21) 0.17
Incorrect ﬁrst-line antimicrobial therapy, n (%) 0 3 (11) 0.56
Surgical treatment
Indication for surgical treatment, n (%) 1 (11) 11 (41) 0.22
Because of mechanical complication (n) 0 2
Because of neurologic complication (n) 1 9
Outcome
Lost to follow-up, n (%) 0 3 (11) 0.56
Time of follow-up (mo), median (range) 48 (7–150) 4 (0.2–90)
Microbiologic success, n (%) 8 (89) 19 (79)* 1
Residual back pain (n) 5 5† 0.23
Failure (n) 1 5*
Death during antimicrobial therapy (n) 0 3
VO-related death (n) 0 3
VO relapse (n) 0 2
Microbiologic failure on another focus of infection (n) 1 0
*Among 24 evaluable outcomes.
†Among 17 cases of evaluable back pain.
574 Clinical Microbiology and Infection, Volume 21 Number 6, June 2015 CMIAll cases of deﬁned VO occurring in OLT recipients (Z944)
were included in the VO-OLT population. A control VO group
(VO-C) was selected among all discharge patients with a VO
diagnosis, with three control patients for one case of VO-OLT
patient. Controls were selected chronologically, corresponding
to the three closest dates of radiologic diagnosis of VO. An
exclusion criterion for the control group was a history of solid
organ transplantation.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectInitial clinical, biologic and radiologic data were collected
for patients in each group, as were follow-up data. Microbi-
ologic success was deﬁned by the absence of relapse (spine
localization or other focus) of infection due to the same
pathogen responsible for VO during follow-up. In case of
death during antimicrobial therapy, or during follow-up and
related to VO complications, clinical outcome was considered
to be failure.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 573–577
CMI Buzelé et al. Osteomyelitis after liver transplantation 575Univariate analysis was performed to assess differences in
characteristics of VO in OLT patients. Comparison among
categorical variable was performed by Fisher’s exact test and
among continuous variables by the Mann-Whitney U test.ResultsDuring the study period, 752 OLT were performed, and VO
occurred in 9 OLT recipients (1.2%). Characteristics of the nine
VO-OLT patients are summarized in Table 1. Median age was
56 (range 28–61) years. Four had diabetes mellitus. Underlying
liver disease leading to OLT were chronic hepatitis C (n = 4),
chronic hepatitis B (n = 2), autoimmune hepatitis (n = 2) and
alcoholic cirrhosis (n = 1), with associated fatty liver disease in
three patients. Two had hepatocellular carcinoma at the time of
OLT. In two cases, OLT was a second procedure. Median
Model for End Stage Liver Disease score at OLT was 24 (range
19–40). Immunosuppressive therapy combined tacrolimus
(n = 9) with mycophenolate mofetil in eight patients and
azathioprine in one patient. Six patients were still receiving
prednisone at the time of VO. Median time from OLT to VO
diagnosis was 12 (range 4–41) weeks. During the time from
OLT to VO, eight patients had at least one infection leading to
antimicrobial therapy (bloodstream infections in six patients,
ventilator-associated pneumonia in three and Clostridium difﬁcile
colitis in ﬁve). Two patients had four courses of antibiotic
therapy, one had three, three had two and two had one course
between OLT and VO.
At the time of diagnosis of VO, eight patients had back pain,
four had fever and none had severe sepsis. Three patients had
neurologic symptoms (radicular neuropathy in two, spinal cord
compression in one). Median time from clinical symptoms of
VO to radiologic diagnosis was 5 (range 1–9) weeks.
At diagnosis, median C-reactive protein (CRP) in VO-OLT
patients was 33 (range 8–187) mg/L, with only two VO-OLT
patients with CRP >50 mg/L; median white blood cells count
was 4.7 (range 3.1–6.8) × 109/L. White blood cell count was
normal (<10 × 109/L, with neutrophils <7.5 × 109/L) in all nine
VO-OLT patients, whereas white blood cell counts were
<10 × 109/L in eight VO-C patients (30%). No data were
available for CD8 and CD4 T cell counts in OLT-VO patients at
the time of diagnosis.
Radiologic ﬁndings on magnetic resonance imaging (n = 8) or
computed tomographic scan (n = 1) included, in addition to
features of VO, epidural abscess in ﬁve patients and para-
vertebral soft tissues abscess in six. Location of VO was lumbar
(n = 4), thoracic (n = 3) or multifocal (n = 2). Microbiologic
diagnosis of VO was deﬁnite for 7 patients. Three patients had
bacterial VO (Staphylococcus aureus in two, Escherichia coli inClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologyone), three had fungal VO (Aspergillus fumigatus in two, Candida
albicans in one) and one had VO due to Mycobacterium tuber-
culosis. Identiﬁcation was done by blood culture in only one case
(S. aureus). The eight other VO-OLT patients had negative
blood culture results at the time of diagnosis. Percutaneous
needle biopsy was performed for six of them and was positive
in four (A. fumigatus, C. albicans, E. coli, M. tuberculosis). In one
case, diagnosis was made on surgical samples taken during
laminectomy (S. aureus). The last patient had multifocal infec-
tion caused by A. fumigatus, and microbiologic diagnosis was
made by assessment of a cutaneous biopsy sample. For the two
patients with negative percutaneous needle biopsy ﬁndings,
there was no microbiologic diagnosis. In four patients, infection
was disseminated in multiple foci: brain and disseminated skin
lesions for one patient with A. fumigatus VO, lung and liver
transplant for one patient with M. tuberculosis VO, infection of a
soft tissue hematoma in one patient with S. aureus VO and knee
arthritis for one patient with C. albicans VO; none had
endocarditis.
Median time from clinical symptoms to antimicrobial therapy
was 6 (range 3–10) weeks. Total duration of treatment was 12
(range 6–88) weeks. Duration of antimicrobial therapy was 12
(range 12–17) weeks for bacterial infections and 60 (range
11–88) weeks for fungal infection. Tuberculosis VO was
treated for 52 weeks. For undocumented VO, an empirical
antimicrobial therapy was based on previous bloodstream in-
fections: daptomycin associated with cefotaxime in one patient
and vancomycin in one, during 6 and 10 weeks, respectively.
With the occurrence of VO in OLT patients, immunosup-
pression tended to be reduced as much as possible. Cortico-
steroids were stopped in 2 patients, and tacrolimus posology
was reduced in 4 other patients, mostly because of drug–drug
interactions (antifungal therapy), including one patient for
whom corticosteroids were stopped and tacrolimus posology
was reduced.
One patient had spinal cord compression leading to surgery,
with laminectomy and spinal osteosynthesis.
Outcome was favourable in eight patients, with microbio-
logic success. One patient experienced relapse of infection at
another focus (Aspergillus fumigatus and brain abscess). Five had
residual back pain, with three requiring morphine. The patient
with osteosynthesis also had neurologic sequelae. One patient
died during follow-up as a result of hepatic failure (18 months
after the end of antimicrobial therapy).
Compared to VO-C, age of VO-OLT patients was lower (p
0.008). CRP level and white blood cell count were lower in
VO-OLT patients (p 0.02, and p < 0.001, respectively). Blood
cultures were less frequently positive in VO-OLT patients
compared to controls (p 0.02). Rate of fungal VO was higher (p
0.01) and rate of bacterial VO lower (p 0.001) among VO-OLTand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 573–577
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group, versus two in the VO-OLT group, without statistical
signiﬁcance. There was also a trend towards higher rate of
multifocal infection in VO-OLT patients (p 0.05) (= 1).
Duration of time from clinical signs to diagnosis and rate of
microbiologic success did not signiﬁcantly differ between the
two groups.DiscussionNine cases of VO occurring in OLT patients are reported
herein. To our knowledge, it is the ﬁrst study describing the
characteristics of VO in this speciﬁc population.
Although clinical presentation was comparable to the con-
trol group, and despite the occurrence of VO during hospital-
ization and close follow-up as a result of liver transplantation,
duration of time from clinical symptoms to diagnosis was not
different between the two groups. CRP level and white blood
cell count were lower than in the control group. In a study
reporting pyogenic VO in immunocompetent patients, no pa-
tient had normal white blood cell count [2]. The lower level of
these blood inﬂammatory markers may be explained by the
immunosuppressive status of the OLT patients and have
probably played a role in the time for imaging and diagnosis of
VO. Lower blood cell count could also be related to residual
hypersplenism during the early posttransplant course and to
mycophenolate mofetil treatment. However, elevation of CRP
level in a liver transplant recipient is strongly suggestive of an
infectious complication, and diagnosis of VO must be
considered.
The trend towards a higher rate of epidural abscess (deﬁned
by dural thickening with ﬁxation of gadolinium or iodine) in the
VO-C group (89% vs. 56%) could be explained by the presence
of a spine surgical unit in our centre with a speciﬁc recruitment
of patients with neurologic signs associated with VO. Indeed,
among the 24 patients with epidural abscess in the VO-C
group, 16 had neurologic signs. This recruitment bias does
not apply to patients who are already followed in our centre
for OLT.
Concerning microbiologic diagnosis, the rate of positive
blood culture was lower in the VO-OLT group despite a trend
towards higher frequency of multifocal infections, leading to a
biopsy procedure (percutaneous or surgical) being performed
to optimize diagnosis. Multiple previous antibiotic therapies
could have played a role in these difﬁculties to obtain micro-
biologic diagnosis [6]. Trend to longer duration of time be-
tween clinical signs and start of antimicrobial therapy in the
VO-OLT patients may thus be partially explained by this
delayed microbiologic diagnosis.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectDifferences in microbiologic epidemiology of causal patho-
gens for VO-OLT patients, notably with the higher rate of
fungal infection, may be explained by patients’ immunocom-
promised status, reﬂected by number of previous infections
before VO. High antibiotic selective pressure related to pre-
vious antibiotic exposure certainly may had an impact [4]. The
high incidence of Clostridium difﬁcile colitis during the time be-
tween OLT and VO also reﬂects this high antibiotic exposure.
Because of the particular epidemiology of VO in this population,
our results emphasize the need for multiplication of samples,
including bacterial, mycobacterial and fungal cultures and his-
tologic study to optimize microbiologic diagnosis.
Despite their immunocompromised status, the rate of
favourable outcome in VO-OLT patients was comparable to
the control group. Few data are available concerning the
duration of antimicrobial therapy for immunocompromised
patients. For bacterial VO, no data suggest longer therapy
duration for these patients [1]. Our results support the deci-
sion not to lengthen the duration of antibiotic therapy in this
population. For fungal VO, no guideline is available for duration
of therapy [7,8]. Considering the Infectious Diseases Society of
America guidelines for Candida spp. and Aspergillus fumigatus–
related osteomyelitis, antifungal therapy must be prolonged
more than 6 to 8 weeks, and up to 12 months, for candidiasis
[9,10]. These guidelines are mostly supported by case series or
reports. In the three fungal VO cases reported herein,
discontinuation of antimicrobial therapy was decided in regard
to clinical and imaging evolution after a median of 60 weeks
without relapse. Because of drug interactions, plasma levels of
calcineurin inhibitors (e.g. tacrolimus and ciclosporin) should
be closely monitored when associated with antifungal
treatment.Transparency declarationAll authors report no conﬂicts of interest relevant to this
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